The Effects of Phosphatidylserine (PS) Expression on HL 60, and the Efficacy of the Role of Doxorubicin (DOX) on HL60| Biomed Grid

Introduction: In recent studies the importance has been shown of the interactions between CD47 expressed on HL60 cells and the inhibitory Protein Kinase C (PKC) (Bisindolylmaleimide I). Study objectives: the study aimed to explore the function of CD47 expressed on HL60 cells and the inhibitory Protein Kinase C (PKC). Methodology: Initially, the expression of Phosphatidylserine (PS) levels in HL60 was analysed. The effect of PS expression on tumour cell growth and programmed cell death was also examined by triggering with BRIC-126 antibody. At the same time, we were able to observe the efficacy of doxorubicin (DOX) on HL60 when combined with other established leukemic drugs. The HL60 cell lines were analysed using flow cytometry to find out how PKC (Bisindolylmaleimide I) was expressed in HL60 and whether that expression was dependent on whether PKC is activated or inhibited. Although the efficacy of DOX on HL60 was clearly demonstrated by the research the mechanism through which it works was not clearly demonstrated. Study Findings: There was an agreement with the view that PKC may have an anti-leukemic affect, and that it may potentially be a therapeutic target in neoplastic cells, although this would require further research specific to those areas. The data collected also tended to agree with the view that DOX could be a useful treatment for some malignant diseases. Conclusion: The results of the present study showed the potential of using PKC as anti-leukemic therapeutic option